|
Katushkina Yu.A., Tatarintseva Z.G., Kosmacheva E.D., Petrik G.G.
Clinical observation of a patient with primary hypoparathyroidism, uncontrolled hypocalcemia and heart failure
|
№6 / 2023
|
|
Demidova T.Yu., Izmailova M.Ya.
The structure of the prevalence of cardiovascular diseases and chronic kidney disease in patients with type 2 diabetes mellitus in the stationary care
|
№8 / 2022
|
|
Alieva A.M., Reznik E.V., Teplova N.V., Totolyan G.G., Gasanova E.T., Kalova M.R., Sabanchieva E.E., Nikitin I.G.
JDP2 – a new promising biological marker in cardiovascular pathology
|
№5 / 2022
|
|
Larina V.N., Larin V.G.
The place of bisoprolol cardioselective beta-adrenoblocker in treatment of patients with different chronic heart failure phenotypes
|
№1 / 2022
|
|
Alieva A.M., Teplova N.V., Kislyakov V.A., Voronkova K.V., Shnakhova L.M., Valiev R.K., Rakhaev A.M., Elmurzaeva D.A., Malkarova D.S., Nikitin I.G.
Biomarkers in cardiology: microRNA and heart failure
|
№1 / 2022
|
|
Alieva A.M., Teplova N.V., Reznik E.V., Valiev R.K., Rakhaev A.M., Kudaeva M.V., Akhmatov I.Z., Arakelyan R.A., Nikitin I.G.
Biomarkers in cardiology: lipocalin associated with neutrophil gelatinase (NGAL) and cardiovascular diseases
|
№1 / 2022
|
|
Salukhov V.V., Khalimov Yu.Sh., Cherkashin D.V., Kadin D.V.
The role of ketonemia induced by sodium-glucose cotransporter 2 inhibitors: from the energy exchange to cardioprotection
|
№10 / 2021
|
|
Larina V.N.
Comorbid patient with chronic heart failure: possibilities of sacubitril/valsartan
|
№6 / 2021
|
|
Shulkina S.G., Kokorin V.A.
New perspectives and real possibilities in the treatment of patients with heart failure
|
№6 / 2021
|
|
Khlynova O.V., Skachkova V.V.
Hyperammonemia in the practice of a therapist and cardiologist: theoretical and practical significance
|
№5 / 2021
|
|
Koltsov A.V., Kalimulin O.A., Tyrenko V.V., Gretskaya E.V., Bologov S.G., Sinopalnikov D.O.
A modern approach to the treatment of heart failure in a patient with heart amyloidosis by valsartan/sakubitril combination
|
№6 / 2019
|
|
I.I. Shaposhnik
Such different sartans. Place of candesartan
|
№2 / 2017
|
Русский
